Nautilus Biotechnology, Inc. (NAUT) News
Filter NAUT News Items
NAUT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NAUT News From Around the Web
Below are the latest news stories about NAUTILUS BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate NAUT as an investment opportunity.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics AwardSociety award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics Parag Mallick, Ph.D. Co-founder and Chief Scientist SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of th |
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell DevelopmentFormer Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Martin Huber, Ph.D. Vice President of Biochemistry and Flow Cell Development SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and |
Nautilus Biotechnology Reports Third Quarter 2023 Financial ResultsSEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. “I’m very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness”, said Sujal Patel, CEO of Nautilus. “Continuing to increase the scale and robustness of the platform remains a key area of focus as we rea |
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the we |
Nautilus Biotechnology to Participate in Upcoming September Investor ConferencesSEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Wednesday, September 13th at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time. Gilmartin Group Emerging Growt |
With 33% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's futureKey Insights Significant insider control over Nautilus Biotechnology implies vested interests in company growth 54% of... |
Nautilus Biotechnology to Participate in Upcoming August Investor ConferencesSEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Canaccord 43rd Annual Growth Conference in Boston, MAManagement will participate in “The Next Generation of Proteomics from the Research and Clinical Perspectives” Panel on Thursday, August 10th at 10:00 a.m. Eastern Time UBS MedTech, Tools a |
Nautilus Biotechnology Reports Second Quarter 2023 Financial ResultsSEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023. “I’m excited by the solid progress we made in Q2 against some of our foundational scientific and development goals and in the ways we continue to prepare ourselves for our commercial launch,” said Sujal Patel, CEO of Nautilus. “The type of transf |
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the w |
Nautilus Biotechnology to Participate in Upcoming June Investor ConferencesSEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Jefferies 2023 Healthcare Conference in New York, NY Fireside chat on Thursday, June 8th at 1:00 p.m. Eastern Time Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CAFireside chat on Monday, June 12th at 4:40 p.m. Pacific |